Ian has been covering a broad range of topics across the Japanese and Asian pharma industry, including corporate, M&A, R&D, pricing and policy developments, since 1988. After a stint as Tokyo-based Japan and Asia editor for Scrip, in 2014 he became managing editor of PharmAsia News (now part of Scrip/Pink Sheet). In his current position, he directs regional coverage for Scrip and Pink Sheet and manages a multinational, on-the-ground team. Ian is a recipient of multiple internal and external awards and a regular participant in APAC conferences, webinars and events, and produces regular podcasts. He has spent the majority of his life in Asia, having grown up in Hong Kong, and enjoys cycling and music.
Latest from Ian Haydock
This week: 2027 medicare price cuts likely not as large as CMS estimates; Zai Lab leads DLL3 lung cancer ADC race; Phase II failure for J&J’s Alzheimer’s asset posdinemab; Bayer's positive Phase III data for asundexian in stroke; and Pfizer/Astellas’s Padcev's first big win in bladder cancer study.
In this week's episode: obesity beyond GLP-1s; biotech leaders bullish as M&A heats up; BMS’s milvexian setback; clinicians on evolution of MASH treatment; and Japan H1 results mixed.
In this week's episode: Pfizer’s unwavering pursuit of Metsera; Lilly’s obesity momentum; Merck & Co.’s MFN negotiations; Novartis’s promising Sjögren’s results; and the rising Chinese pressure on US innovation.
In this week's episode: third quarter dealmaking picks up; Novartis still has M&A firepower even after Avidity acquisition; Hanmi’s obesity contender shows Phase III promise; NVIDIA partnership progresses Lilly’s AI plans; and Lilly builds gene therapy push with Adverum buy.
This week a focus on the European Society for Medical Oncology meeting in Berlin: Enhertu in early-stage breast cancer; Padcev/Keytruda in bladder cancer; Phase III wins for Pluvicto; Trodelvy and Datroway in breast cancer tussle; and Merck & Co. raises hopes in breast cancer.
Innovent sees huge new alliance with "best partner" Takeda as providing a major boost to its globalization ambitions.